GE HealthCare Technologies Inc. (NASDAQ: GEHC) has been under pressure over the past year. Shares trade near $76 as growth has cooled and investor sentiment has softened. Even with the recent pullback, analysts still expect the company to deliver steady improvement as margins stabilize and demand holds firm across its imaging and diagnostics businesses.
Recently, GE HealthCare highlighted momentum in precision care and AI driven imaging tools. These innovations are gaining traction with hospitals looking for faster and more accurate diagnostics. The company also advanced its cost efficiency program, reinforcing its focus on disciplined execution heading into 2026. These developments show that GEHC is strengthening its competitive position despite a slower capital spending environment.
This article outlines where Wall Street analysts believe the stock could trade by 2027. We reference consensus expectations and TIKR’s Guided Valuation Model based on analysts’ average estimates. These figures reflect Street assumptions, not TIKR’s own predictions.
Find out what a stock’s really worth in under 60 seconds with TIKR’s new Valuation Model (It’s free) >>>
Analyst Price Targets Suggest Modest Upside
GEHC trades around $76 today. The latest average analyst price target is $88, which implies about 16% upside and places the stock in the modest upside category.
- High estimate: $108
- Low estimate: $78
- Median target: $88
- Ratings: 12 Buys, 3 Outperforms, 6 Holds
For investors, this setup points to a steady but measured outlook. Analysts believe GEHC can move higher if revenue trends improve and margins hold at current levels. Upside is achievable, but larger gains would require stronger equipment demand or a more meaningful recovery in hospital spending.
Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
GE HealthCare Growth Outlook and Valuation
The company’s fundamentals appear steady, supported by consistent revenue expectations and stable margin forecasts. Analysts model mid single digit growth with a balanced profit profile that reflects GEHC’s strong installed base and recurring service revenue.
- Revenue is projected to grow about 4.5% annually through 2027
- Operating margins are expected to hold near 16.2%
- Shares trade at 15.9x forward earnings based on the valuation model
- Based on analysts’ average estimates, TIKR’s Guided Valuation Model using a 15.9x forward P E suggests GEHC could reach about $91 by 2027
- That implies roughly 19% total upside, or about 8% annualized returns
These numbers suggest GEHC can compound steadily without needing rapid acceleration. The stock benefits from predictable service revenue and a large global footprint, which help smooth out slower equipment cycles. For investors, GEHC looks like a reliable healthcare operator with a stable return profile, though further upside would likely require stronger procedure volumes or clearer margin expansion.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
What’s Driving the Optimism?
GE HealthCare benefits from consistent demand across imaging, ultrasound and diagnostics. Its service revenue tied to a broad installed base provides stability even when hospitals delay new equipment purchases. Recent momentum in AI assisted imaging and precision care solutions also strengthens GEHC’s long term positioning.
Management’s focus on efficiency and cost control helps maintain margin stability. For investors, these strengths create a foundation for gradual improvement without relying on high growth cycles. GEHC has the tools to rebuild earnings at a steady pace.
Bear Case: Growth and Competitive Pressure
Despite these positives, GEHC still operates in a low growth environment. Hospitals remain cautious with large equipment orders, and competitors continue to push aggressively across global markets. Slower spending cycles and pricing pressure can limit the company’s ability to expand margins.
For investors, the concern is that GEHC may deliver stable results but struggle to unlock stronger upside. Without clear signs of accelerating growth or margin expansion, the stock may continue to trade within a predictable range.
Outlook for 2027: What Could GE HealthCare Be Worth?
Based on analysts’ average estimates, TIKR’s Guided Valuation Model suggests GEHC could trade near $91 by 2027. That represents about 19% total upside and around 8% annualized returns.
While this outlook reflects a reasonable recovery path, it already assumes consistent execution and stable margins. For investors hoping for stronger gains, GEHC would need better operating leverage or a noticeable improvement in equipment demand. Without those catalysts, returns will likely remain steady but limited.
GEHC remains a dependable long term healthcare name. The stock offers stability, predictable cash flow and a clear path to moderate compounding. However, outsized gains depend on management driving stronger growth across its core product lines.
AI Compounders With Massive Upside That Wall Street Is Overlooking
Everyone wants to cash in on AI. But while the crowd chases the obvious names benefiting from AI like NVIDIA, AMD, or Taiwan Semiconductor, the real opportunity may lie on the AI application layer where a handful of compounders are quietly embedding AI into products people already use every day.
TIKR just released a new free report on 5 undervalued compounders that analysts believe could deliver years of outperformance as AI adoption accelerates.
Inside the report, you’ll find:
- Businesses already turning AI into revenue and earnings growth
- Stocks trading below fair value despite strong analyst forecasts
- Unique picks most investors haven’t even considered
If you want to catch the next wave of AI winners, this report is a must-read.
Find out what your favorite stocks are really worth (Free with TIKR) >>>
